•  

LAB150

Webinar: Staying on Target – How to Determine if Your Research Program is Ready for Drug Delivery

Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development November 17, 2020 - 12-1:30 PM ET Register here: bit.ly/Stay-On-Target In the first of three webinars in the LAB150 series on drug discovery and development, we focus on the initial steps on the long path of bringing a new drug to market and to patients in need. Specifically, we examine approaches to target identification and target validation. Target ID describes ... Read more

Funding for Sinai Health Netherton Syndrome project from partners AmorChem and Evotec

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ... Read more

LAB150 adds project with focus on mental health

Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take effect, if at all. This exciting new project hopes to develop a novel rapid-acting antidepressant that has the potential to provide patient relief much faster than conventional treatments. The project builds on years of research led by Dr. ... Read more

LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ... Read more